Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (Coxibs) are commonly used for minor pain treatment and chronically in the management of rheumatoid arthritis and osteoarthritis. Three areas of safety concerns are shared by both groups of drugs: Gastrointestinal complications (upper gastrointestinal bleeding, perforations or obstruction), cardiovascular safety (mainly myocardial infarction) and renal safety (acute renal failure, hypertension and electrolyte abnormalities). The incidence of renal complications may be increased two-fold with NSAIDs or coxibs, and there is no evidence for a major difference between the two groups of drugs. Coxibs are clearly associated with improved gastrointestinal safety compared to NSAIDs, but this benefit is reduced and may be lost completely with concurrent low-dose aspirin use. In contrast, coxibs may be associated with a greater incidence of cardiovascular complications, mainly myocardial infarction, especially in comparison to certain NSAIDs such as naproxen. Thus, coxibs are not generally safer than NSAIDs. Rather, their long-term use should be customized to individual patients and their intrinsic baseline risks and other medications required in their management.
Keywords: drug safety, renal safety, gastrointestinal safety, cardiovascular safety, nsaid, cox inhibitor, coxib
Current Topics in Medicinal Chemistry
Title: Global Safety of Coxibs and NSAIDs
Volume: 5 Issue: 5
Author(s): K. Pham and R. Hirschberg
Affiliation:
Keywords: drug safety, renal safety, gastrointestinal safety, cardiovascular safety, nsaid, cox inhibitor, coxib
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (Coxibs) are commonly used for minor pain treatment and chronically in the management of rheumatoid arthritis and osteoarthritis. Three areas of safety concerns are shared by both groups of drugs: Gastrointestinal complications (upper gastrointestinal bleeding, perforations or obstruction), cardiovascular safety (mainly myocardial infarction) and renal safety (acute renal failure, hypertension and electrolyte abnormalities). The incidence of renal complications may be increased two-fold with NSAIDs or coxibs, and there is no evidence for a major difference between the two groups of drugs. Coxibs are clearly associated with improved gastrointestinal safety compared to NSAIDs, but this benefit is reduced and may be lost completely with concurrent low-dose aspirin use. In contrast, coxibs may be associated with a greater incidence of cardiovascular complications, mainly myocardial infarction, especially in comparison to certain NSAIDs such as naproxen. Thus, coxibs are not generally safer than NSAIDs. Rather, their long-term use should be customized to individual patients and their intrinsic baseline risks and other medications required in their management.
Export Options
About this article
Cite this article as:
Pham K. and Hirschberg R., Global Safety of Coxibs and NSAIDs, Current Topics in Medicinal Chemistry 2005; 5 (5) . https://dx.doi.org/10.2174/1568026054201640
DOI https://dx.doi.org/10.2174/1568026054201640 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characteristics and Risk Factors Associated with Stroke Subtypes among Adult Patients Admitted to the Stroke Unit of Jimma University Medical Center: A Retrospective Cross-sectional Study
Current Hypertension Reviews New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry 5-HT and NA Reuptake Inhibitors and Appetite Regulation: The Role of the Central 5-HT Network
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adherence to Mediterranean Diet Offers an Additive Protection Over the Use of Statin Therapy: Results from the ATTICA Study (2002-2012)
Current Vascular Pharmacology Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: A True Effect or a Bias? A Systematic Review & Meta-Analysis
Current Neuropharmacology Aberrant DNA Methylation Pattern may Enhance Susceptibility to Migraine: A Novel Perspective
CNS & Neurological Disorders - Drug Targets Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Optimizing the Management of Uncontrolled/Resistant Hypertension. The Importance of Sleep Apnoea Syndrome
Current Vascular Pharmacology Matrix Metalloproteinases in Lung Diseases
Current Protein & Peptide Science